Evercore ISI analyst Josh Schimmer downgraded Neurocrine Biosciences to In Line from Outperform with a price target of $130, down from $140. Neurocrine shares have outperformed the broader indices, appreciating 50% over the past six months, Schimmer tells investors in a research note. The analyst says "nothing stands out to us as being able to deliver compelling diversification away from Ingrezza" in next year’s clinical readouts.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NBIX:
- Jefferies pharma/biopharma analysts hold analyst/industry conference call
- Neurocrine price target raised to $101 from $78 at BMO Capital
- Neurocrine price target raised to $120 from $110 at Wells Fargo
- Neurocrine price target raised to $117 from $101 at RBC Capital
- Neurocrine price target raised to $132 from $127 at Cantor Fitzgerald